ECM
BCLI

ExodusPoint Capital Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

ExodusPoint Capital Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-846
Closed -$48K – 2117
2021
Q2 		$48K Buy
+846
New +$45.2K ﹤0.01% 2225
2020
Q2 		– Sell
-707
Closed -$49K – 1771
2020
Q1 		$49K Buy
+707
New +$55.2K ﹤0.01% 957

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ExodusPoint Capital Management's BCLI Position: Q3 2021 in Review

ExodusPoint Capital Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2021, closing a stake of 846 shares — an estimated $48K sold.

ExodusPoint Capital Management first reported a position in BCLI in Q1 2020 and held it in 2 quarters. The position peaked at $49K in Q1 2020. 52 funds tracked by Wall St. Rank hold BCLI as of Q3 2021.

  • ExodusPoint Capital Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2021 after selling out during the quarter.
  • ExodusPoint Capital Management sold 846 BRAINSTORM CELL THERAPUTC shares in Q3 2021, an estimated $48K.
  • ExodusPoint Capital Management first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2020 and held it in 2 quarters.
  • ExodusPoint Capital Management's BRAINSTORM CELL THERAPUTC position peaked at $49K in Q1 2020.
  • 52 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2021.

Based on ExodusPoint Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.